Glycation of apoprotein A-I is associated with coronary artery plaque progression in type 2 diabetic patients

Diabetes Care

Volumn 36, Issue 5, 2013, Pages 1312-1320

  Pu, Li Jin ^a,b   Lu, Lin ^a,b   Zhang, Rui Yan ^a   Du, Run ^a   Shen, Ying ^a   Zhang, Qi ^a   Yang, Zheng Kun ^a   Chen, Qiu Jing ^b   Shen, Wei Feng ^a,b  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; CHOLESTEROL ACYLTRANSFERASE; GLUCOSE; HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHATIDYLCHOLINE;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; CORONARY ARTERY PLAQUE; DENSITOMETRY; DIABETIC PATIENT; DISEASE ASSOCIATION; ENZYME ACTIVITY; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INTRAVASCULAR ULTRASOUND; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHOSPHOLIPID BLOOD LEVEL; PROTEIN GLYCOSYLATION; QUANTITATIVE ANALYSIS;

APOLIPOPROTEIN A-I; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY VESSELS; DIABETES MELLITUS, TYPE 2; FEMALE; GLYCOSYLATION; HUMANS; MALE; PLAQUE, ATHEROSCLEROTIC;

EID: 84876783625     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-1411     Document Type: Article

References (38)

1. Natarajan P, Ray KK, Cannon CP. High-density lipoprotein and coronary heart disease: current and future therapies. J Am Coll Cardiol 2010;55:1283-1299
2. Sorci-Thomas MG, Bhat S, Thomas MJ. Activation of lecithin:cholesterol acyl-transferase by HDL ApoA-I central helices. Clin Lipidol 2009;4:113-124
3. Jones MK, Catte A, Li L, Segrest JP. Dynamics of lecithin:cholesterol acyl-transferase activation by apolipoprotein A-I. Biochemistry 2009;48:11196-11210
4. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414:813-820 (Pubitemid 34000785)
5. Nobécourt E, Tabet F, Lambert G, et al. Nonenzymatic glycation impairs the an-tiinflammatory properties of apolipopro-tein A-I. Arterioscler Thromb Vasc Biol 2010;30:766-772
6. Hedrick CC, Thorpe SR, Fu MX, et al. Glycation impairs high-density lipopro-tein function. Diabetologia 2000;43:312-320 (Pubitemid 30163474)
7. Shaw JA, Bobik A, Murphy A, et al. Infusion of reconstituted high-density lipo-protein leads to acute changes in human atherosclerotic plaque. Circ Res 2008; 103:1084-1091
8. Patel S, Drew BG, Nakhla S, et al. Reconstituted high-density lipoprotein increases plasma high-density lipoprotein anti-inflammatory properties and cholesterol efflux capacity in patients with type 2 diabetes. J Am Coll Cardiol 2009;53:962-971
9. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003;26(Suppl.1): S5-S20
10. Chobanian AV, Bakris GL, Black HR, et al.; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206-1252 (Pubitemid 37553153)
11. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497
12. Service FJ, Rizza RA, Zimmerman BR, Dyck PJ, O'Brien PC, Melton LJ 3rd. The classification of diabetes by clinical and C-peptide criteria. A prospective population-based study. Diabetes Care 1997;20:198-201 (Pubitemid 27051563)
13. Scanlon PJ, Faxon DP, Audet AM, et al. ACC/AHA guidelines for coronary angi-ography. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on Coronary Angiography). Developed in collaboration with the Society for Cardiac Angiography and Interventions. J Am Coll Cardiol 1999;33: 1756-1824
14. American Diabetes Association. Standards of medical care in diabetesd2008. Diabetes Care 2008;31(Suppl. 1):S12-S54
15. Buse JB, Ginsberg HN, Bakris GL, et al.; American Heart Association; American Diabetes Association. Primary prevention of cardiovascular diseases in people with diabetes mellitus: A scientific statement from the American Heart Association and the American Diabetes Association. Circulation 2007;115:114-126 (Pubitemid 46058619)
16. Garg P, Normand SL, Silbaugh TS, et al. Drug-eluting or bare-metal stenting in patients with diabetes mellitus: results from the Massachusetts Data Analysis Center Registry. Circulation 2008;118: 2277-2285, 7p, 2285
17. Lu L, Pu LJ, Zhang Q, et al. Increased glycated albumin and decreased esRAGE levels are related to angiographic severity and extent of coronary artery disease in patients with type 2 diabetes. Atherosclerosis 2009;206:540-545
18. Waters D, Lespérance J, Craven TE, Hudon G, Gillam LD. Advantages and limitations of serial coronary arteriogra-phy for the assessment of progression and regression of coronary atherosclerosis. Implications for clinical trials. Circulation 1993;87(Suppl.):II38-II47 (Pubitemid 23068570)
19. Berry C, L'Allier PL, Grégoire J, et al. Comparison of intravascular ultrasound and quantitative coronary angiography for the assessment of coronary artery disease progression. Circulation 2007;115: 1851-1857 (Pubitemid 46598898)
20. Waters D, Higginson L, Gladstone P, et al. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. Circulation 1994;89: 959-968
21. Solymoss BC, Bourassa MG, Campeau L, et al. Effect of increasing metabolic syndrome score on atherosclerotic risk profile and coronary artery disease an-giographic severity. Am J Cardiol 2004; 93:159-164 (Pubitemid 38058723)
22. Du R, Zhang RY, Zhu ZB, et al. Impact of angiographic and intravascular ultrasound features on clinical outcome after sirolimus-eluting stent implantation for de-novo lesions in nondiabetic and type 2 diabetic patients. Coron Artery Dis 2010; 21:175-181
23. Hirohata A, Yamamoto K, Miyoshi T, et al. Impact of olmesartan on progression of coronary atherosclerosis a serial volumetric intravascular ultrasound analysis from the OLIVUS (impact of OLmesarten on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) trial. J Am Coll Cardiol 2010;55: 976-982
24. Ren S, Shen GX. Impact of antioxidants and HDL on glycated LDL-induced generation of fibrinolytic regulators from vascular endothelial cells. Arterioscler Thromb Vasc Biol 2000;20:1688-1693 (Pubitemid 30353906)
25. Luhtala N, Parker R. LSM1 over-expression in Saccharomyces cerevisiae depletes U6 snRNA levels. Nucleic Acids Res 2009; 37:5529-5536
26. Teerlink T, Barto R, Ten Brink HJ, Schalkwijk CG. Measurement of Nepsilon-(carboxymethyl)lysine and Nepsilon-(car-boxyethyl)lysine in human plasma protein by stable-isotope-dilution tandem mass spectrometry. Clin Chem 2004;50:1222-1228 (Pubitemid 38824231)
27. Manabe M, Abe T, Nozawa M, Maki A, Hirata M, Itakura H. New substrate for determination of serum lecithin:choles-terol acyltransferase. J Lipid Res 1987;28: 1206-1215 (Pubitemid 17151583)
28. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008; 27:157-172 (Pubitemid 351193639)
29. von Birgelen C, Hartmann M, Mintz GS, Baumgart D, Schmermund A, Erbel R. Relation between progression and regression of atherosclerotic left main coronary artery disease and serum cholesterol levels as assessed with serial longterm (. or =12 months) follow-up in-travascular ultrasound. Circulation 2003; 108:2757-2762 (Pubitemid 37498977)
30. Azen SP, Mack WJ, Cashin-Hemphill L, et al. Progression of coronary artery disease predicts clinical coronary events. Long-term follow-up from the Cholesterol Lowering Atherosclerosis Study. Circulation 1996;93:34-41 (Pubitemid 26006565)
31. Böse D, von Birgelen C, Erbel R. In-travascular ultrasound for the evaluation of therapies targeting coronary atherosclerosis. J Am Coll Cardiol 2007;49:925-932
32. Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: A randomized controlled trial. JAMA 2003;290:2292-2300 (Pubitemid 37430562)
33. Nissen SE, Tardif JC, Nicholls SJ, et al.; ILLUSTRATE Investigators. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007;356: 1304-1316 (Pubitemid 46513296)
34. Nobecourt E, Davies MJ, Brown BE, et al. The impact of glycation on apolipoprotein A-I structure and its ability to activate lecithin:cholesterol acyltransferase. Dia-betologia 2007;50:643-653 (Pubitemid 46215509)
35. Park KH, Cho KH. High-density lipopro-tein (HDL) from elderly and reconstituted HDL containing glycated apolipoproteins A-I share proatherosclerotic and prosen-escent properties with increased cholesterol influx. J Gerontol A Biol Sci Med Sci 2011; 66:511-520
36. Sasongko MB, Wong TY, Nguyen TT, et al. Serum apolipoproteins are associated with systemic and retinal microvascular function in people with diabetes. Diabetes 2012;61: 1785-1792
37. Weers PMM, Patel AB, Wan LC, et al. Novel N-terminal mutation of human apolipoprotein A-I reduces self-association and impairs LCAT activation. J Lipid Res 2011;52:35-44
38. Roosbeek S, Vanloo B, Duverger N, et al. Three arginine residues in apolipoprotein A-I are critical for activation of lecithin: cholesterol acyltransferase. J Lipid Res 2001;42:31-40 (Pubitemid 32142858)